Profile data is unavailable for this security.
About the company
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
- Revenue in HKD (TTM)2.83bn
- Net income in HKD-952.12m
- Incorporated2019
- Employees3.53k
- LocationAkeso IncNo. 6Shennong Road, Torch Development ZoneZhongshan 528437ChinaCHN
- Phone+86 76 089873998
- Fax+86 76 089873900
- Websitehttps://www.akesobio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genscript Biotech Corp | 4.31bn | 644.26m | 27.27bn | 5.77k | 40.98 | 0.7872 | 46.59 | 6.32 | 0.3043 | 11.43 | 2.01 | 15.84 | 0.1259 | 5.94 | 4.39 | 774,328.20 | 0.3949 | -9.75 | 0.4933 | -13.19 | 51.78 | 52.05 | 3.14 | -46.54 | 1.90 | 1.18 | 0.0471 | -- | 6.07 | 16.81 | -115.90 | -- | 5.78 | -- |
| TransThera Sciences (Nanjing) Inc | 0.00 | -266.83m | 29.27bn | 121.00 | -- | 44.43 | -- | -- | -0.6723 | -0.6723 | 0.00 | 1.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.89 | -- | 0.0052 | -- | -100.00 | -- | 20.03 | -- | -- | -- |
| Shanghai Bao Pharmaceuticals Co Ltd | 52.51m | -427.94m | 31.98bn | -- | -- | 31.94 | -- | 608.98 | -1.31 | -1.31 | 0.1611 | 3.07 | -- | -- | -- | -- | -- | -- | -- | -- | 97.96 | -- | -814.93 | -- | 2.07 | -- | 0.2168 | -- | -11.11 | -- | -127.21 | -- | -- | -- |
| Akeso Inc | 2.83bn | -952.12m | 93.31bn | 3.53k | -- | 12.55 | -- | 33.02 | -1.08 | -1.08 | 3.22 | 8.07 | 0.2115 | 0.7726 | 3.95 | 931,028.30 | -7.07 | -8.38 | -8.20 | -9.82 | 79.26 | -- | -33.46 | -33.18 | 4.01 | -536.98 | 0.4168 | -- | -53.08 | 97.39 | -125.37 | -- | 34.14 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.69bn | -812.75m | 97.98bn | 1.87k | -- | 17.36 | -- | 58.02 | -3.63 | -3.63 | 7.49 | 24.20 | 0.3067 | 4.93 | 13.37 | 919,399.90 | -14.76 | -- | -17.11 | -- | 57.10 | -- | -48.12 | -- | 6.32 | -- | 0.0255 | -- | 25.48 | -- | 53.54 | -- | -- | -- |
| WuXi Biologics (Cayman) Inc | 22.57bn | 4.72bn | 155.24bn | 12.55k | 33.72 | 3.02 | 20.74 | 6.88 | 1.11 | 1.11 | 5.38 | 12.43 | 0.3442 | 6.36 | 3.06 | 1,794,821.00 | 8.45 | 7.98 | 10.57 | 9.95 | 42.65 | 42.71 | 24.54 | 25.82 | 2.69 | -- | 0.0943 | 0.00 | 9.63 | 36.21 | -1.28 | 27.05 | 3.97 | -- |
Data as of Feb 06 2026. Currency figures normalised to Akeso Inc's reporting currency: Hong Kong Dollar HKD
18.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Green Court Capital Management Ltd.as of 25 Sep 2024 | 43.14m | 4.68% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 26.68m | 2.90% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 22.24m | 2.41% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 14.24m | 1.55% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 11.78m | 1.28% |
| Schroder Investment Management Ltd.as of 30 Nov 2025 | 11.45m | 1.24% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 11.30m | 1.23% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 10.74m | 1.17% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 10.70m | 1.16% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 9.02m | 0.98% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
